Condition: Head and Neck Squamous Cell Carcinoma (HNSCC) · Pancreatic Adenocarcinoma · Non-small Cell Lung Cancer (NSCLC) · Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617 (REC-617) in participants with advanced solid tumors.
This description comes directly from the study's public registry record.
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. · 385-374-1724 · clinicaltrials@recursionpharma.com
Always discuss trial participation with your own doctor first.
| USC Norris Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| START Midwest | Grand Rapids, Michigan, United States | Recruiting |
| START San Antonio | San Antonio, Texas, United States | Recruiting |
| START Mountain Region | West Valley City, Utah, United States | Recruiting |
| GZA Ziekenhuizen - Campus Sint-Augustinus | Antwerp, Belgium | Recruiting |
| Clinique Universitaires Saint-Luc | Brussels, Belgium | Recruiting |
| Institute Jules Bordet | Brussels, Belgium | Recruiting |
| CHU Sart Tilman | Liège, Belgium | Recruiting |
| The Beatson West of Scotland Cancer Centre | Glasgow, United Kingdom | Recruiting |
| UCL Hospitals NHS Foundation Trust | London, United Kingdom | Recruiting |
| The Christie NHS Foundation Trust | Manchester, United Kingdom | Recruiting |
| Newcastle Upon Tyne NHS Foundation Trust | Newcastle upon Tyne, United Kingdom | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05985655